244 related articles for article (PubMed ID: 3497285)
1. Induction of lymphokine-activated killer activities in peripheral blood lymphocytes and regional lymph node lymphocytes against PC-9 cultured adenocarcinoma and autologous pulmonary adenocarcinoma cells.
Morikawa Y; Watanabe S; Kodama T
Jpn J Clin Oncol; 1987 Jun; 17(2):129-39. PubMed ID: 3497285
[TBL] [Abstract][Full Text] [Related]
2. Tumor-draining lymph nodes of primary lung cancer patients: a potent source of tumor-specific killer cells and dendritic cells.
Kimura H; Dobrenkov K; Iida T; Suzuki M; Ando S; Yamamoto N
Anticancer Res; 2005; 25(1A):85-94. PubMed ID: 15816523
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity tests against cultured human lung cancer cells with autologous lymphocytes activated in vitro by mitomycin C-treated tumor monolayers in the presence of T-cell growth factor.
Kimura H; Yamaguchi Y; Kadoyama C; Sato N; Fujisawa T
Jpn J Clin Oncol; 1983 Mar; 13(1):3-13. PubMed ID: 6300483
[TBL] [Abstract][Full Text] [Related]
5. [Clinical features and inhibitory activity of regional lymph node cells on the cytotoxicity of autologous killer cells in patients with primary lung cancer].
Kadoyama C; Kimura H; Yamaguchi Y
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2906-11. PubMed ID: 2959205
[TBL] [Abstract][Full Text] [Related]
6. Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy.
Hong WS; Kim CM; Lee JO; Kang TW; Yun TK; Kim CY
Jpn J Clin Oncol; 1990 Mar; 20(1):87-93. PubMed ID: 2108272
[TBL] [Abstract][Full Text] [Related]
7. Functional character and augmentation of lymphocytes in regional lymph nodes of patients with lung cancer.
Watanabe Y; Hashizume Y; Shimizu J; Yoshida M; Watanabe S; Iwa T; Sakai S; Migita S; Sato H; Murayama T
Am Rev Respir Dis; 1990 Oct; 142(4):769-74. PubMed ID: 2221581
[TBL] [Abstract][Full Text] [Related]
8. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic activity of various LAK cells against autologous lung cancer, K-562 and Daudi cells.
Kimura H; Yamaguchi Y
Jpn J Clin Oncol; 1989 Sep; 19(3):222-8. PubMed ID: 2810822
[TBL] [Abstract][Full Text] [Related]
10. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.
Rivoltini L; Gambacorti-Passerini C; Squadrelli-Saraceno M; Grosso MI; Cantù G; Molinari R; Orazi A; Parmiani G
Cancer Res; 1990 Sep; 50(17):5551-7. PubMed ID: 2386961
[TBL] [Abstract][Full Text] [Related]
11. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes.
Anderson TM; Ibayashi Y; Tokuda Y; Colquhoun SD; Holmes EC; Golub SH
Cancer Res; 1988 Mar; 48(5):1180-3. PubMed ID: 3257716
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
13. Autologous high-killing cytotoxic T lymphocytes against human lung cancer are induced using interleukin (IL)-1beta, IL-2, IL-4, and IL-6: possible involvement of dendritic cells.
Saijo Y; Hong X; Tanaka M; Tazawa R; Liu SQ; Saijo K; Ohno T; Koike K; Ohkuda K; Satoh K; Nukiwa T
Clin Cancer Res; 1999 May; 5(5):1203-9. PubMed ID: 10353758
[TBL] [Abstract][Full Text] [Related]
14. Lymphokine-activated killer-cell function of lymphocytes from peripheral blood, regional lymph nodes and tumor tissues of patients with oral cancer.
Tatake RJ; Krishnan N; Rao RS; Fakih AR; Gangal SG
Int J Cancer; 1989 Apr; 43(4):560-6. PubMed ID: 2522911
[TBL] [Abstract][Full Text] [Related]
15. [Antitumor activity of human tumor infiltrating lymphocytes (TIL) and its comparison with peripheral blood lymphocytes (PBL)].
Xu ZY
Zhonghua Zhong Liu Za Zhi; 1990 Sep; 12(5):345-7. PubMed ID: 2177396
[TBL] [Abstract][Full Text] [Related]
16. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
17. [Treatment with autologous tumor-infiltrating lymphocytes and recombinant interleukin-2 in patients with lung carcinoma].
Li D; Zhang X; Song Y
Zhonghua Zhong Liu Za Zhi; 1995 Mar; 17(2):152-5. PubMed ID: 7656811
[TBL] [Abstract][Full Text] [Related]
18. In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.
McMannis JD; Fisher RI; Creekmore SP; Braun DP; Harris JE; Ellis TM
J Immunol; 1988 Feb; 140(4):1335-40. PubMed ID: 3257776
[TBL] [Abstract][Full Text] [Related]
19. Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors.
Rayner AA; Grimm EA; Lotze MT; Wilson DJ; Rosenberg SA
J Natl Cancer Inst; 1985 Jul; 75(1):67-75. PubMed ID: 2989604
[TBL] [Abstract][Full Text] [Related]
20. [The characteristic of lymphokine-activated killer cells induced from tumor draining lymph-node cell].
Meng YG; Fu CY; Wang YZ
Zhonghua Fu Chan Ke Za Zhi; 1994 Sep; 29(9):535-7, 574. PubMed ID: 7835130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
